生物分析
背景(考古学)
灵活性(工程)
数据共享
数据科学
计算机科学
药物发现
纳米技术
化学
知识管理
制药工业
蛋白质检测
工程类
表征(材料科学)
鉴定(生物学)
计算生物学
管理科学
作者
Amanda Wilson,Richard Lucey,Emmanuel Njumbe Ediage,Katrin Schroeter,Szabolcs Szarka,Peter Blattmann,Paul J. Boersema,Kees J. Bronsema,Gregor Jordan,Sebastian Malchow,David Pekar,Heike Wiese,Bryan Marks,Frank Schalk,Marie Reille-Seroussi,Ana Villar Garea,Nico van de Merbel,Lieve Dillen,Philip Timmerman
出处
期刊:Bioanalysis
[Future Science Ltd]
日期:2026-05-03
卷期号:18 (7): 561-569
标识
DOI:10.1080/17576180.2026.2683269
摘要
The use of liquid chromatography–mass spectrometry for quantitative large-molecule bioanalysis has increased substantially over the past decade, driven by its ability to address analytical challenges that may be difficult to resolve using traditional ligand-binding assays. In this European Bioanalysis Forum perspective, seven case studies from pharmaceutical companies and contract research organizations illustrate the fit-for-purpose application of LC–MS across different stages of drug development. These include isoform-specific quantification, subclass-resolved immunoglobulin profiling, characterization of post-translational modifications, assessment of in vivo biotherapeutic integrity, and multiplexed analysis in complex biological matrices. Collectively, the examples highlight how LC–MS can support selectivity, structural insight, and analytical flexibility when aligned with the specific context of use. The EBF aims to foster continued scientific exchange by encouraging the sharing of such case studies across its community.
科研通智能强力驱动
Strongly Powered by AbleSci AI